Search in:

International Journal of Nanomedicine Volume 13, 2018 - Issue

Submit an article Journal homepage

Open access

190

Views

CrossRef citations to date

Altmetric

Original Research

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

Haitao Pan1 School of Pharmaceutical Sciences;2 Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Jiayu Liu1 School of Pharmaceutical Sciences;2 Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Wentong Deng1 School of Pharmaceutical Sciences;2 Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Jieyu Xing1 School of Pharmaceutical Sciences;2 Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Qing Li1 School of Pharmaceutical Sciences;2 Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]

Zhong Wang1 School of Pharmaceutical Sciences;2 Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]

Pages 3189-3201 | Published online: 29 May 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (25)

Ana Mora‐Boza, Zakir Ahmedin & Andrés J. García. (2023) Controlled release of therapeutic antibody using hydrolytically degradable microgels. Journal of Biomedical Materials Research Part A 112:8, pages 1265-1275.
Crossref

Ying Cong, Nick Devoogdt, Philippe Lambin, Ludwig J. Dubois & Ala Yaromina. (2024) Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management. Cancers 16:2, pages 371.
Crossref

Daniel V. Kalinovsky, Irina V. Kholodenko, Elena V. Svirshchevskaya, Alexey V. Kibardin, Dmitry Yu. Ryazantsev, Fedor N. Rozov, Sergey S. Larin, Sergey M. Deyev & Roman V. Kholodenko. (2023) Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment–Drug Conjugates Carrying Maytansinoids DM1 and DM4. Current Issues in Molecular Biology 45:10, pages 8112-8125.
Crossref

Nidiane Dantas Reis Prado, Nairo Brilhante-Da-Silva, Rosa Maria Oliveira Sousa, Michelle Suelen da Silva Morais, Sibele Andrade Roberto, Marcos Barros Luiz, Livia Coelho de Assis, Anna Carolina M. Marinho, Luiz Felipe Lemes de Araujo, Rafael de Souza Pontes, Rodrigo Guerino Stabeli, Carla Freire Celedonio Fernandes & Soraya dos Santos Pereira. (2023) Single-domain antibodies applied as antiviral immunotherapeutics. Journal of Virological Methods 320, pages 114787.
Crossref

Yanting Zhang, Shaoqi Yang, Dan Jiang, Yanning Li, Shuo Ma, Liyan Wang, Guangqi Li, Hongxia Wang, Aijun Zhang & Guangxian Xu. (2023) Screening and identification of an anti-PD-1 nanobody with antitumor activity. Bioscience Reports 43:1.
Crossref

Amirhosein Maali, Monireh Gholizadeh, Saba Feghhi-Najafabadi, Ahmad Noei, Seyedeh Sheila Seyed-Motahari, Shafieeh Mansoori & Zahra Sharifzadeh. (2023) Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Frontiers in Immunology 14.
Crossref

Iris M. Hagemans, Peter J. Wierstra, Kas Steuten, Janneke D. M. Molkenboer-Kuenen, Duco van Dalen, Martin ter Beest, Johan M. S. van der Schoot, Olga Ilina, Martin Gotthardt, Carl G. Figdor, Ferenc A. Scheeren, Sandra Heskamp & Martijn Verdoes. (2022) Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. Journal of Nanobiotechnology 20:1.
Crossref

Francisca Mulero, Marta Oteo, Guillermo Garaulet, Natalia Magro, Lluvia Rebollo, Guillermo Medrano, Clara Santiveri, Eduardo Romero, Ricela E. Sellek, Yago Margolles, Ramón Campos-Olivas, Alicia G. Arroyo, Luis Angel Fernández, Miguel Angel Morcillo & Jorge L. Martínez-Torrecuadrada. (2022) Development of anti-membrane type 1-matrix metalloproteinase nanobodies as immunoPET probes for triple negative breast cancer imaging. Frontiers in Medicine 9.
Crossref

Zaria Malindi, Stefan Barth & Heidi Abrahamse. (2022) The Potential of Antibody Technology and Silver Nanoparticles for Enhancing Photodynamic Therapy for Melanoma. Biomedicines 10:9, pages 2158.
Crossref

Hantao Lou & Xuetao Cao. (2022) Antibody variable region engineering for improving cancer immunotherapy. Cancer Communications 42:9, pages 804-827.
Crossref

Bingxuan Li, Xiaohong Qin & Li-Zhi Mi. (2022) Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development. Nanoscale 14:19, pages 7110-7122.
Crossref

Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D’Huyvetter, Sophie Hernot, Nick Devoogdt & Karine Breckpot. 2022. New Antibody Formats. New Antibody Formats 143 199 .

Guangfa Bao, Ming Tang, Jun Zhao & Xiaohua Zhu. (2021) Nanobody: a promising toolkit for molecular imaging and disease therapy. EJNMMI Research 11:1.
Crossref

Giles Vermeire, Elien De Smidt, Peter Casteels, Nick Geukens, Paul Declerck & Kevin Hollevoet. (2020) DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration. Cancer Gene Therapy 28:7-8, pages 828-838.
Crossref

Tahereh Zadeh Mehrizi & Kamran Mousavi Hosseini. (2021) An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review. Nanoscale Advances 3:13, pages 3730-3745.
Crossref

Haofei Hong, Chen Li, Liang Gong, Jinfeng Wang, Dan Li, Jie Shi, Zhifang Zhou, Zhaohui Huang & Zhimeng Wu. (2021) Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy. Chemical Science 12:12, pages 4623-4630.
Crossref

Zi-Wen Han, Zhi-Wu Lyv, Bin Cui, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhao-Wu Ma, Xian-Wang Wang, Xiao-Chun Peng, Shu-Zhong Cui, Ying Xiang, Mo Yang & Hong-Wu Xin. (2020) The old CEACAMs find their new role in tumor immunotherapy. Investigational New Drugs 38:6, pages 1888-1898.
Crossref

Tiantian Wu, Manman Liu, Hai Huang, Yaping Sheng, Haihua Xiao & Yangzhong Liu. (2020) Clustered nanobody–drug conjugates for targeted cancer therapy. Chemical Communications 56:65, pages 9344-9347.
Crossref

Emily Y. Yang & Khalid Shah. (2020) Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology 10.
Crossref

Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin & Jo Caers. (2020) Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology 11.
Crossref

Irina V. Kholodenko, Daniel V. Kalinovsky, Elena V. Svirshchevskaya, Igor I. Doronin, Maria V. Konovalova, Alexey V. Kibardin, Tatyana V. Shamanskaya, Sergey S. Larin, Sergey M. Deyev & Roman V. Kholodenko. (2019) Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies. Molecules 24:21, pages 3835.
Crossref

Jiayu Liu, Xiaoqiong Wu, Limin Lin, Haitao Pan, Yanlan Wang, Yumei Li, Yining Zhao & Zhong Wang. (2019) Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities. Molecular Therapy - Oncolytics 14, pages 66-73.
Crossref

Alanod D. AlQahtani, David O’Connor, Alexander Domling & Sayed K. Goda. (2019) Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomedicine & Pharmacotherapy 113, pages 108750.
Crossref

Timothée Chanier & Patrick Chames. (2019) Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer. Antibodies 8:1, pages 13.
Crossref

Vidyanand Anaparti. (2018) Anti-GPCR Antibodies. Materials and Methods 8.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

Articles from other publishers (25)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

Citations (25)

Articles from other publishers (25)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date